RecruitingNon-Hodgkin LymphomaChronic Lymphocytic LeukaemiaMultiple Myeloma
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Eligible age
All ages
Accepts
All genders
Locations
4 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.
Sponsor: Bristol-Myers Squibb
You may qualify if…
- ✓ Participant has received a commercially available Bristol-Myers Squibb (BMS) manufactured Gene Modified Cell Therapy (GMCT) and has been diagnosed with a qualifying second primary malignancy or a second primary malignancy which BMS has qualified for testing.
- ✓ Participant has received a commercially available BMS manufactured GMCT in a clinical trial or other investigational setting (including non-conforming product) for which there is no testing protocol in place for that trial or investigational setting and has been diagnosed with a qualifying second primary malignancy or a second primary malignancy which BMS has qualified for testing.
You may not qualify if…
- ✕ Participant is actively participating in a clinical trial where information and sample collection is being conducted under that clinical trial.
- ✕ Participant has not received a BMS manufactured GMCT or has not been diagnosed with a qualifying second primary malignancy.
Where it's recruiting
Source: ClinicalTrials.gov · NCT06357754 · last updated 2026-01-22